In This Issue
Journal: Cancer Discovery (2022)

In This Issue| July 06 2022 In This Issue Author & Article Information Online Issn: 2159-8290 Print Issn: 2159-8274 ©2022 American Association for Cancer Research.2022American Association for Cancer Research. Cancer Discov (2022) 12 (7): 1599–1601. https://doi.org/10.1158/2159-8290.CD-12-7-ITI Related Content A commentary has been published: Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts A commentary has been published: Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1 A commentary has been published: IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment View more A commentary has been published: Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer A commentary has been published: Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients A commentary has been published: Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer A commentary has been published: Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations A commentary has been published: SETD2 Haploinsufficiency Enhances Germinal Center–Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis A commentary has been published: MOZ and Menin–MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record July 6 2022 Citation In This Issue. Cancer Discov 1 July 2022; 12 (7): 1599–1601. https://doi.org/10.1158/2159-8290.CD-12-7-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Unlike metastatic colorectal cancer (mCRC) with microsatellite instability or mismatch repair (MMR) deficiency and subsequent high tumor mutation burden, microsatellite-stable and MMR-proficient mCRC is typically refractory to immune checkpoint blockade. As preclinical studies revealed that temozolomide (TMZ) leads to MMR deficiency and increased tumor mutation burden and subsequently sensitizes to immunotherapy, Crisafulli, Sartore-Bianchi, Lazzari, and colleagues initiated the ARETHUSA clinical trial in which patients with O6-methylguanine-DNA-methyltransferase (MGMT)–deficient, MMR-proficient, RAS-mutant mCRC were primed with TMZ prior to treatment with immunotherapy and demonstrate proof of concept that a TMZ-induced mutational signature and increased tumor mutational burden could be detected in tumor biopsies and blood following TMZ priming. Four of 6 patients treated to date with pembrolizumab after TMZ priming experienced disease stabilization. See article, p. 1656. EGFR exon 20 insertion mutations (EGFRexon20ins) account for approximately 2% of non–small cell lung cancer (NSCLC), with limited effective therapies. Wang and... You do not currently have access to this content.